MASCT by Hengrui Yuanzheng Biotechnology for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Kidney Cancer (Renal Cell Cancer).

NEJM aims to hold AI to account with new publication

One of the most prestigious names in medical publishing is going all in on artificial intelligence. The New England Journal of Medicine on Monday will

December 11, 2023

Can At-Home Vision Tests Detect Active Neovascular AMD?

Three at-home vision-monitoring tools failed to detect worsening neovascular age-related macular degeneration (AMD), a diagnostic-test accuracy study reported. The paper-based KeepSight Journal from the International

May 3, 2024

Qiagen, AstraZeneca expand companion diagnostic pact beyond cancer

Dive Brief: Qiagen said Wednesday it has expanded its collaboration with AstraZeneca to cover companion diagnostics for chronic diseases. The agreement, which moves the partnership

August 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.